Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer
A two arm, multi centric, randomized, open label, parallel, multiple dose pharmacodynamic study in premenopausal patients with advanced breast cancer.
Breast Cancer
DRUG: Goserelin acetate 3.6 mg Injection|DRUG: ZOLADEXÂ® 3.6mg Injection
To evaluate and compare the pharmacodynamics, Percentage of patients with a mean estradiol concentration \<30 pg/mL at day 85 days (EOS), 85 days
A phase III, two arm, multi centric, randomized, open label, parallel, multiple dose pharmacodynamic study in premenopausal patients with breast cancer